<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01525771</url>
  </required_header>
  <id_info>
    <org_study_id>AMC-XPID-1</org_study_id>
    <nct_id>NCT01525771</nct_id>
  </id_info>
  <brief_title>Safety Study of Combined Systemic and Intraperitoneal Chemotherapy to Treat Stomach Cancer</brief_title>
  <acronym>XPID</acronym>
  <official_title>A Phase I-II Study of Systemic Capecitabine, Cisplatin and Intraperitoneal Docetaxel (XPID) in Patients With Advanced Stomach Cancer With Peritoneal Seeding</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A maximum of 8 cycles of chemotherapy will be administered. Depending on patients'
      tolerability, 8 cycles of chemotherapy will be given to the patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single-center, open-label, prospective, single-arm, phase I-II study

      About 37 patients (Phase I 18, Phase II 31 (including 12 patients from Phase I)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose</measure>
    <time_frame>1 year</time_frame>
    <description>Phase I Study
- Maximum tolerated dose of Intraperitoneal Docetaxel
Phase II Study
Progression-free survival rate at 6 months
response rate, time to progression, overall survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety profile</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>efficacy</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Stage IV Gastric Cancer With Metastasis</condition>
  <arm_group>
    <arm_group_label>No intervention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Single-center, open-label, prospective, single-arm, phase I-II study</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>The study medication will be administered every 3 weeks for a maximum of 8cycles. A study medication will be given to the patients.
Docetaxel (-1 to 3 level)mg/m2 IV(D1) every 21 days (-1 level: 40, 1 level: 60, 2 level: 80, 3 level: 100)
Xeloda 937.5 mg/m2/ day PO, twice a day(D1-D14) every 21 days
Cisplatin 60mg/m2 IV (D1) every 21 days</description>
    <arm_group_label>No intervention</arm_group_label>
    <other_name>XP with Intraperitoneal Docetaxel</other_name>
    <other_name>Capecitabine</other_name>
    <other_name>Cisplatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Unresectable or metastatic advanced gastric adenocarcinoma confirmed by histology

          2. Peritoneal seeding proven by histology or cytology

          3. Completion of adjuvant chemotherapy 6 months before the study, or no previous
             chemotherapy (But, patients who received docetaxel or cisplatin as adjuvant
             chemotherapy should be excluded)

          4. Age 18 to 70 years old

          5. Eastern Cooperative Oncology Group performance status &lt;_ 2

          6. Estimated life expectancy of more than 3 months

          7. Adequate bone marrow function (WBCs&gt;3,000/µL and absolute neutrophil count (ANC)
             &gt;1,500/µL and platelets&gt;100,000/µL),

          8. Adequate renal function: creatinine &lt; 1 x upper normal limit (UNL) or creatinine
             clearance _&gt; 60ml/min

          9. Adequate hepatic function: bilirubin &lt; 1.5 x UNL, AST/ALT levels &lt; 2.5 x UNL, alkaline
             phosphatase &lt; 5 x UNL (except in case of bone metastasis without any liver disease)

         10. Written informed consent

        Exclusion Criteria:

          1. Contraindication to any drug contained in the chemotherapy regimen

          2. Other tumor type than adenocarcinoma

          3. Presence or history of CNS metastasis

          4. Gastric outlet or bowel obstruction

          5. Evidence of serious gastrointestinal bleeding

          6. Peripheral neuropathy &gt; grade 2

          7. History of significant neurologic or psychiatric disorders

          8. History of another malignancy within the last five years except cured basal cell
             carcinoma of skin and cured carcinoma in-situ of uterine cervix

          9. Pregnant or lactating women, women of childbearing potential not employing adequate
             contraception

         10. Other serious illness or medical conditions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min-Hee Ryu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center/Univ of Ulsan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2011</study_first_submitted>
  <study_first_submitted_qc>February 1, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2012</study_first_posted>
  <last_update_submitted>June 26, 2015</last_update_submitted>
  <last_update_submitted_qc>June 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Min-Hee Ryu</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Advanced Gastric cancer</keyword>
  <keyword>Xeloda (Capecitabine)</keyword>
  <keyword>Cisplatin</keyword>
  <keyword>Taxotere (Docetaxel)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

